オハイオにおける神経芽腫の臨床試験
オハイオ内の拠点で、神経芽腫に関する8件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他4件
被験者募集中第3相
30歳以下 · 全性別 · 2026/10/02更新 · NCT06172296Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- 他3件
被験者募集中第3相
365 Days – 30 Years · 全性別 · 2026/08/25更新 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第2相
1歳〜39歳 · 全性別 · 2026/08/24更新 · NCT07635056SPEARHEAD-3 Pediatric Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
2歳〜21歳 · 全性別 · 2026/08/11更新 · NCT05642455NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
1歳〜31歳 · 全性別 · 2026/07/20更新 · NCT06450041Neuroblastoma Biology Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中観察研究
31 Days – 99 Years · 全性別 · 2026/03/23更新 · NCT01587300A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
18 Months – 40 Years · 全性別 · 2025/08/12更新 · NCT05135975ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。